Alpha Cognition

Q2 FY2026 EarningsQ2 FY2026 results were in-line with consensus on the top line but missed significantly on bottom-line and margin metrics. Revenue reached $6.09M (essentially meeting the $6.11M consensus) driven by a 251% YoY surge in ZUNVEYL prescription volume. However, Gross Margin of 93.6% slightly beat the 91.7% estimate, while GAAP EPS of -$0.40 was roughly in-line with the -$0.39 expected. High operating burn continues as the company ramps commercialization, with Cash From Operations at -$18.66M for the first half, significantly wider than consensus expectations.